O	0	4	High	High	JJ	B-NP
O	4	5	-	-	HYPH	I-NP
O	5	10	grade	grade	NN	I-NP
B-Cancer	11	16	clear	clear	JJ	I-NP
I-Cancer	17	21	cell	cell	NN	I-NP
I-Cancer	22	27	renal	renal	JJ	I-NP
I-Cancer	28	32	cell	cell	NN	I-NP
I-Cancer	33	42	carcinoma	carcinoma	NN	I-NP
O	43	46	has	have	VBZ	B-VP
O	47	48	a	a	DT	B-NP
O	49	55	higher	high	JJR	I-NP
O	56	66	angiogenic	angiogenic	JJ	I-NP
O	67	75	activity	activity	NN	I-NP
O	76	80	than	than	IN	B-PP
O	81	84	low	low	JJ	B-NP
O	84	85	-	-	HYPH	I-NP
O	85	90	grade	grade	NN	I-NP
B-Cancer	91	96	renal	renal	JJ	I-NP
I-Cancer	97	101	cell	cell	NN	I-NP
I-Cancer	102	111	carcinoma	carcinoma	NN	I-NP
O	112	117	based	base	VBN	B-VP
O	118	120	on	on	IN	B-PP
O	121	139	histomorphological	histomorphological	JJ	B-NP
O	140	154	quantification	quantification	NN	I-NP
O	155	158	and	and	CC	I-NP
O	159	162	qRT	qRT	NN	I-NP
O	162	163	-	-	HYPH	B-NP
O	163	166	PCR	PCR	NN	I-NP
O	167	171	mRNA	mRNA	NN	I-NP
O	172	182	expression	expression	NN	I-NP
O	183	190	profile	profile	NN	I-NP
O	190	191	.	.	.	O

B-Cancer	192	197	Clear	Clear	JJ	B-NP
I-Cancer	198	202	cell	cell	NN	I-NP
I-Cancer	203	208	renal	renal	JJ	I-NP
I-Cancer	209	213	cell	cell	NN	I-NP
I-Cancer	214	223	carcinoma	carcinoma	NN	I-NP
O	224	225	(	(	(	O
B-Cancer	225	227	CC	CC	NN	B-NP
I-Cancer	227	228	-	-	HYPH	B-NP
I-Cancer	228	231	RCC	RCC	NN	I-NP
O	231	232	)	)	)	O
O	233	235	is	be	VBZ	B-VP
O	236	237	a	a	DT	B-NP
O	238	244	highly	highly	RB	I-NP
O	245	257	vascularised	vascularise	VBN	I-NP
B-Cancer	258	264	tumour	tumour	NN	I-NP
O	265	268	and	and	CC	O
O	269	271	is	be	VBZ	B-VP
O	272	281	therefore	therefore	RB	B-ADVP
O	282	284	an	an	DT	B-NP
O	285	295	attractive	attractive	JJ	I-NP
O	296	303	disease	disease	NN	I-NP
O	304	306	to	to	TO	B-VP
O	307	312	study	study	VB	I-VP
O	313	325	angiogenesis	angiogenesis	NN	B-NP
O	326	329	and	and	CC	O
O	330	332	to	to	TO	B-VP
O	333	337	test	test	VB	I-VP
O	338	343	novel	novel	JJ	B-NP
O	344	356	angiogenesis	angiogenesis	NN	I-NP
O	357	367	inhibitors	inhibitor	NNS	I-NP
O	368	370	in	in	IN	B-PP
O	371	376	early	early	JJ	B-NP
O	377	385	clinical	clinical	JJ	I-NP
O	386	397	development	development	NN	I-NP
O	397	398	.	.	.	O

B-Cell	399	410	Endothelial	Endothelial	JJ	B-NP
I-Cell	411	415	cell	cell	NN	I-NP
O	416	429	proliferation	proliferation	NN	I-NP
O	430	435	plays	play	VBZ	B-VP
O	436	437	a	a	DT	B-NP
O	438	445	pivotal	pivotal	JJ	I-NP
O	446	450	role	role	NN	I-NP
O	451	453	in	in	IN	B-PP
O	454	457	the	the	DT	B-NP
O	458	465	process	process	NN	I-NP
O	466	468	of	of	IN	B-PP
O	469	481	angiogenesis	angiogenesis	NN	B-NP
O	481	482	.	.	.	O

O	483	486	The	The	DT	B-NP
O	487	490	aim	aim	NN	I-NP
O	491	493	of	of	IN	B-PP
O	494	498	this	this	DT	B-NP
O	499	504	study	study	NN	I-NP
O	505	508	was	be	VBD	B-VP
O	509	511	to	to	TO	B-VP
O	512	519	compare	compare	VB	I-VP
O	520	532	angiogenesis	angiogenesis	NN	B-NP
O	533	543	parameters	parameter	NNS	I-NP
O	544	546	in	in	IN	B-PP
O	547	550	low	low	JJ	B-NP
B-Cellular_component	551	558	nuclear	nuclear	JJ	I-NP
O	559	564	grade	grade	NN	I-NP
O	565	566	(	(	(	O
O	566	567	n	n	NN	B-NP
O	567	568	=	=	SYM	B-VP
O	568	570	87	87	CD	B-NP
O	570	571	)	)	)	O
O	572	574	vs	vs	IN	B-PP
O	575	579	high	high	JJ	B-NP
B-Cellular_component	580	587	nuclear	nuclear	JJ	I-NP
O	588	593	grade	grade	NN	I-NP
B-Cancer	594	596	CC	CC	NN	I-NP
I-Cancer	596	597	-	-	HYPH	O
I-Cancer	597	600	RCC	RCC	NN	B-NP
O	601	602	(	(	(	O
O	602	603	n	n	NN	B-NP
O	603	604	=	=	SYM	B-VP
O	604	606	63	63	CD	B-NP
O	606	607	)	)	)	O
O	607	608	.	.	.	O

O	609	610	A	A	DT	B-NP
O	611	616	panel	panel	NN	I-NP
O	617	619	of	of	IN	B-PP
O	620	630	antibodies	antibody	NNS	B-NP
O	631	634	was	be	VBD	B-VP
O	635	639	used	use	VBN	I-VP
O	640	643	for	for	IN	B-PP
O	644	664	immunohistochemistry	immunohistochemistry	NN	B-NP
O	664	665	:	:	:	O
O	666	670	CD34	CD34	NN	B-NP
O	670	671	/	/	SYM	B-NP
O	671	673	Ki	Ki	NN	I-NP
O	673	674	-	-	SYM	B-NP
O	674	676	67	67	CD	B-NP
O	676	677	,	,	,	O
O	678	686	carbonic	carbonic	JJ	B-NP
O	687	696	anhydrase	anhydrase	NN	I-NP
O	697	699	IX	IX	CD	I-NP
O	699	700	,	,	,	O
O	701	708	hypoxia	hypoxia	NN	B-NP
O	708	709	-	-	HYPH	O
O	709	718	inducible	inducible	JJ	B-NP
O	719	725	factor	factor	NN	I-NP
O	725	726	-	-	HYPH	O
O	726	732	1alpha	1alpha	NN	B-NP
O	733	734	(	(	(	O
O	734	737	HIF	HIF	NN	B-NP
O	737	738	-	-	HYPH	B-NP
O	738	744	1alpha	1alpha	NN	I-NP
O	744	745	)	)	)	O
O	746	749	and	and	CC	O
O	750	758	vascular	vascular	JJ	B-NP
O	759	770	endothelial	endothelial	JJ	I-NP
O	771	777	growth	growth	NN	I-NP
O	778	784	factor	factor	NN	I-NP
O	785	786	(	(	(	O
O	786	790	VEGF	VEGF	NN	B-NP
O	790	791	)	)	)	O
O	791	792	.	.	.	O

B-Multi-tissue_structure	793	799	Vessel	Vessel	NN	B-NP
O	800	807	density	density	NN	I-NP
O	808	809	(	(	(	O
O	809	812	MVD	MVD	NN	B-NP
O	813	814	-	-	HYPH	B-NP
B-Tissue	815	826	microvessel	microvessel	NN	I-NP
O	827	834	density	density	NN	I-NP
O	834	835	)	)	)	O
O	835	836	,	,	,	O
B-Cell	837	848	endothelial	endothelial	JJ	B-NP
I-Cell	849	853	cell	cell	NN	I-NP
O	854	867	proliferation	proliferation	NN	I-NP
O	868	876	fraction	fraction	NN	I-NP
O	877	878	(	(	(	O
O	878	881	ECP	ECP	NN	B-NP
O	881	882	%	%	NN	I-NP
O	882	883	)	)	)	O
O	884	887	and	and	CC	O
B-Cell	888	894	tumour	tumour	NN	B-NP
I-Cell	895	899	cell	cell	NN	I-NP
O	900	913	proliferation	proliferation	NN	I-NP
O	914	922	fraction	fraction	NN	I-NP
O	923	924	(	(	(	O
O	924	927	TCP	TCP	NN	B-NP
O	927	928	%	%	NN	I-NP
O	928	929	)	)	)	O
O	930	934	were	be	VBD	B-VP
O	935	943	assessed	assess	VBN	I-VP
O	943	944	.	.	.	O

O	945	949	mRNA	mRNA	NN	B-NP
O	950	960	expression	expression	NN	I-NP
O	961	967	levels	level	NNS	I-NP
O	968	970	of	of	IN	B-PP
O	971	983	angiogenesis	angiogenesis	NN	B-NP
O	984	995	stimulators	stimulator	NNS	I-NP
O	996	999	and	and	CC	I-NP
O	1000	1010	inhibitors	inhibitor	NNS	I-NP
O	1011	1015	were	be	VBD	B-VP
O	1016	1026	determined	determine	VBN	I-VP
O	1027	1029	by	by	IN	B-PP
O	1030	1042	quantitative	quantitative	JJ	B-NP
O	1043	1045	RT	RT	NN	I-NP
O	1045	1046	-	-	HYPH	B-NP
O	1046	1049	PCR	PCR	NN	I-NP
O	1049	1050	.	.	.	O

O	1051	1055	High	High	JJ	B-NP
O	1055	1056	-	-	HYPH	I-NP
O	1056	1061	grade	grade	NN	I-NP
B-Cancer	1062	1064	CC	CC	NN	I-NP
I-Cancer	1064	1065	-	-	HYPH	B-NP
I-Cancer	1065	1068	RCC	RCC	NN	I-NP
O	1069	1075	showed	show	VBD	B-VP
O	1076	1077	a	a	DT	B-NP
O	1078	1084	higher	high	JJR	I-NP
O	1085	1088	ECP	ECP	NN	I-NP
O	1088	1089	%	%	NN	I-NP
O	1090	1091	(	(	(	O
O	1091	1092	P	P	NN	B-NP
O	1092	1093	=	=	SYM	B-VP
O	1093	1094	0	0	CD	B-NP
O	1094	1095	.	.	SYM	I-NP
O	1095	1098	049	049	CD	I-NP
O	1098	1099	)	)	)	O
O	1099	1100	,	,	,	O
O	1101	1102	a	a	DT	B-NP
O	1103	1109	higher	high	JJR	I-NP
O	1110	1113	TCP	TCP	NN	I-NP
O	1113	1114	%	%	NN	I-NP
O	1115	1116	(	(	(	O
O	1116	1117	P	P	NN	B-NP
O	1117	1118	=	=	SYM	B-VP
O	1118	1119	0	0	CD	B-NP
O	1119	1120	.	.	SYM	I-NP
O	1120	1123	009	009	CD	I-NP
O	1123	1124	)	)	)	O
O	1124	1125	,	,	,	O
O	1126	1127	a	a	DT	B-NP
O	1128	1134	higher	high	JJR	I-NP
O	1135	1139	VEGF	VEGF	NN	I-NP
O	1140	1147	protein	protein	NN	I-NP
O	1148	1158	expression	expression	NN	I-NP
O	1159	1160	(	(	(	O
O	1160	1161	P	P	NN	B-NP
O	1162	1166	less	less	JJR	B-NP
O	1167	1171	than	than	IN	I-NP
O	1172	1173	0	0	CD	I-NP
O	1173	1174	.	.	.	I-NP
O	1174	1177	001	001	CD	I-NP
O	1177	1178	)	)	)	O
O	1178	1179	,	,	,	O
O	1180	1181	a	a	DT	B-NP
O	1182	1187	lower	low	JJR	I-NP
O	1188	1191	MVD	MVD	NN	I-NP
O	1192	1193	(	(	(	O
O	1193	1194	P	P	NN	B-NP
O	1195	1199	less	less	JJR	B-NP
O	1200	1204	than	than	IN	I-NP
O	1206	1207	0	0	CD	I-NP
O	1207	1208	.	.	.	I-NP
O	1208	1211	001	001	CD	I-NP
O	1211	1212	)	)	)	O
O	1213	1216	and	and	CC	O
O	1217	1218	a	a	DT	B-NP
O	1219	1224	lower	low	JJR	I-NP
O	1225	1228	HIF	HIF	NN	I-NP
O	1228	1229	-	-	HYPH	I-NP
O	1229	1235	1alpha	1alpha	NN	I-NP
O	1236	1243	protein	protein	NN	I-NP
O	1244	1254	expression	expression	NN	I-NP
O	1255	1256	(	(	(	O
O	1256	1257	P	P	NN	B-NP
O	1257	1258	=	=	SYM	B-VP
O	1258	1259	0	0	CD	B-NP
O	1259	1260	.	.	.	O
O	1260	1263	002	002	CD	B-NP
O	1263	1264	)	)	)	O
O	1265	1269	than	than	IN	B-PP
O	1270	1273	low	low	JJ	B-NP
O	1273	1274	-	-	HYPH	I-NP
O	1274	1279	grade	grade	NN	I-NP
B-Cancer	1280	1282	CC	CC	NN	I-NP
I-Cancer	1282	1283	-	-	HYPH	B-NP
I-Cancer	1283	1286	RCC	RCC	NN	I-NP
O	1286	1287	.	.	.	O

O	1288	1294	Growth	Growth	NN	B-NP
O	1295	1301	factor	factor	NN	I-NP
O	1302	1306	mRNA	mRNA	NN	I-NP
O	1307	1317	expression	expression	NN	I-NP
O	1318	1326	analyses	analysis	NNS	I-NP
O	1327	1335	revealed	reveal	VBD	B-VP
O	1336	1337	a	a	DT	B-NP
O	1338	1344	higher	high	JJR	I-NP
O	1345	1355	expression	expression	NN	I-NP
O	1356	1358	of	of	IN	B-PP
O	1359	1371	angiopoietin	angiopoietin	NN	B-NP
O	1372	1373	2	2	CD	I-NP
O	1374	1376	in	in	IN	B-PP
O	1377	1380	low	low	JJ	B-NP
O	1380	1381	-	-	HYPH	I-NP
O	1381	1386	grade	grade	NN	I-NP
B-Cancer	1387	1389	CC	CC	NN	I-NP
I-Cancer	1389	1390	-	-	HYPH	B-NP
I-Cancer	1390	1393	RCC	RCC	NN	I-NP
O	1393	1394	.	.	.	O

B-Tissue	1395	1406	Microvessel	Microvessel	NN	B-NP
O	1407	1414	density	density	NN	I-NP
O	1415	1418	and	and	CC	O
O	1419	1422	ECP	ECP	NN	B-NP
O	1422	1423	%	%	NN	I-NP
O	1424	1428	were	be	VBD	B-VP
O	1429	1438	inversely	inversely	RB	I-VP
O	1439	1449	correlated	correlate	VBN	I-VP
O	1450	1451	(	(	(	O
O	1451	1454	Rho	Rho	NN	B-NP
O	1454	1455	=	=	SYM	B-VP
O	1455	1456	-	-	SYM	B-NP
O	1456	1457	0	0	CD	I-NP
O	1457	1458	.	.	SYM	I-NP
O	1458	1460	26	26	CD	I-NP
O	1460	1461	,	,	,	O
O	1462	1463	P	P	NN	B-NP
O	1463	1464	=	=	SYM	B-VP
O	1464	1465	0	0	CD	B-NP
O	1465	1466	.	.	SYM	I-NP
O	1466	1469	001	001	CD	I-NP
O	1469	1470	)	)	)	O
O	1470	1471	.	.	.	O

O	1472	1479	Because	Because	IN	B-PP
O	1480	1482	of	of	IN	I-PP
O	1483	1486	the	the	DT	B-NP
O	1487	1496	imperfect	imperfect	JJ	I-NP
O	1497	1508	association	association	NN	I-NP
O	1509	1511	of	of	IN	B-PP
B-Cellular_component	1512	1519	nuclear	nuclear	JJ	B-NP
O	1520	1525	grade	grade	NN	I-NP
O	1526	1529	and	and	CC	I-NP
O	1530	1533	ECP	ECP	NN	I-NP
O	1533	1534	%	%	NN	I-NP
O	1535	1537	or	or	CC	I-NP
O	1538	1541	MVD	MVD	NN	I-NP
O	1541	1542	,	,	,	O
B-Cancer	1543	1545	CC	CC	NN	B-NP
I-Cancer	1545	1546	-	-	HYPH	B-NP
I-Cancer	1546	1549	RCC	RCC	NN	I-NP
O	1550	1553	was	be	VBD	B-VP
O	1554	1558	also	also	RB	I-VP
O	1559	1566	grouped	group	VBN	I-VP
O	1567	1572	based	base	VBN	B-PP
O	1573	1575	on	on	IN	B-PP
O	1576	1579	low	low	JJ	B-NP
O	1579	1580	/	/	SYM	I-NP
O	1580	1584	high	high	JJ	I-NP
O	1585	1588	MVD	MVD	NN	I-NP
O	1589	1592	and	and	CC	O
O	1593	1596	ECP	ECP	NN	B-NP
O	1596	1597	%	%	NN	I-NP
O	1597	1598	.	.	.	O

O	1599	1603	This	This	DT	B-NP
O	1604	1612	analysis	analysis	NN	I-NP
O	1613	1621	revealed	reveal	VBD	B-VP
O	1622	1623	a	a	DT	B-NP
O	1624	1630	higher	high	JJR	I-NP
O	1631	1641	expression	expression	NN	I-NP
O	1642	1644	of	of	IN	B-PP
B-Multi-tissue_structure	1645	1651	vessel	vessel	NN	B-NP
O	1652	1662	maturation	maturation	NN	I-NP
O	1663	1666	and	and	CC	O
O	1667	1680	stabilisation	stabilisation	NN	B-NP
O	1681	1688	factors	factor	NNS	I-NP
O	1689	1690	(	(	(	O
O	1690	1699	placental	placental	JJ	B-NP
O	1700	1706	growth	growth	NN	I-NP
O	1707	1713	factor	factor	NN	I-NP
O	1713	1714	,	,	,	O
O	1715	1721	PDGFB1	PDGFB1	NN	B-NP
O	1721	1722	,	,	,	O
O	1723	1735	angiopoietin	angiopoietin	NN	B-NP
O	1736	1737	1	1	CD	I-NP
O	1737	1738	)	)	)	O
O	1739	1741	in	in	IN	B-PP
B-Cancer	1742	1744	CC	CC	NN	B-NP
I-Cancer	1744	1745	-	-	HYPH	B-NP
I-Cancer	1745	1748	RCC	RCC	NN	I-NP
O	1749	1753	with	with	IN	B-PP
O	1754	1758	high	high	JJ	B-NP
O	1759	1762	MVD	MVD	NN	I-NP
O	1762	1763	,	,	,	O
O	1764	1765	a	a	DT	B-NP
O	1766	1771	group	group	NN	I-NP
O	1772	1774	of	of	IN	B-PP
B-Cancer	1775	1777	CC	CC	NN	B-NP
I-Cancer	1777	1778	-	-	HYPH	B-NP
I-Cancer	1778	1781	RCC	RCC	NN	I-NP
O	1782	1788	highly	highly	RB	B-VP
O	1789	1797	enriched	enrich	VBN	I-VP
O	1798	1800	in	in	IN	B-PP
O	1801	1804	low	low	JJ	B-NP
B-Cellular_component	1805	1812	nuclear	nuclear	JJ	I-NP
O	1813	1818	grade	grade	NN	I-NP
B-Cancer	1819	1821	CC	CC	NN	I-NP
I-Cancer	1821	1822	-	-	HYPH	B-NP
I-Cancer	1822	1825	RCC	RCC	NN	I-NP
O	1825	1826	,	,	,	O
O	1827	1831	with	with	IN	B-PP
O	1832	1835	low	low	JJ	B-NP
O	1836	1839	ECP	ECP	NN	I-NP
O	1839	1840	%	%	NN	I-NP
O	1840	1841	.	.	.	O

O	1842	1845	Our	Our	PRP$	B-NP
O	1846	1853	results	result	NNS	I-NP
O	1854	1861	suggest	suggest	VBP	B-VP
O	1862	1875	heterogeneity	heterogeneity	NN	B-NP
O	1876	1878	in	in	IN	B-PP
O	1879	1889	angiogenic	angiogenic	JJ	B-NP
O	1890	1898	activity	activity	NN	I-NP
O	1899	1902	and	and	CC	O
B-Multi-tissue_structure	1903	1909	vessel	vessel	NN	B-NP
O	1910	1920	maturation	maturation	NN	I-NP
O	1921	1923	of	of	IN	B-PP
B-Cancer	1924	1926	CC	CC	NN	B-NP
I-Cancer	1926	1927	-	-	HYPH	B-NP
I-Cancer	1927	1930	RCC	RCC	NN	I-NP
O	1930	1931	,	,	,	O
O	1932	1934	to	to	TO	B-PP
O	1935	1936	a	a	DT	B-NP
O	1937	1942	large	large	JJ	I-NP
O	1943	1949	extent	extent	NN	I-NP
O	1950	1956	linked	link	VBN	B-VP
O	1957	1959	to	to	TO	B-PP
B-Cellular_component	1960	1967	nuclear	nuclear	JJ	B-NP
O	1968	1973	grade	grade	NN	I-NP
O	1973	1974	,	,	,	O
O	1975	1978	and	and	CC	O
O	1978	1979	,	,	,	O
O	1980	1984	with	with	IN	B-PP
O	1985	1993	probable	probable	JJ	B-NP
O	1994	2005	therapeutic	therapeutic	JJ	I-NP
O	2006	2018	implications	implication	NNS	I-NP
O	2018	2019	.	.	.	O

